PPH — VanEck Pharmaceutical ETF
Data updated: 2026-05-28
PPH — VanEck Pharmaceutical ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. Global (incl. US) Health Care Equity · $1.29B AUM · 0.36% expense ratio · 16.7% 1-yr return. From SEC regulatory filings.
PPH Fund Overview
PPH — VanEck Pharmaceutical ETF is a US ETF managed by VanEck ETF Trust, categorised as Global (incl. US) Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: VanEck ETF Trust
- Category: Global (incl. US) Health Care Equity
- Assets under management: $1.29B
- 1-year return: 16.7%
- Ticker: PPH
- SEC CIK: 0001137360
- SEC series ID: S000034409
- Share class ID: C000105867
PPH Holdings
Top 10 holdings of VanEck Pharmaceutical ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Eli Lilly & Co | 18.70% |
| Novartis AG | 10.76% |
| Merck & Co Inc | 9.68% |
| Pfizer Inc | 5.23% |
| Novo Nordisk A/S | 4.81% |
| Sanofi SA | 4.73% |
| Bristol-Myers Squibb Co | 4.62% |
| Gsk PLC | 4.58% |
| AstraZeneca PLC | 4.40% |
| Johnson & Johnson | 4.34% |
PPH Portfolio Allocation
Asset-class allocation of VanEck Pharmaceutical ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.7% |
| Cash & Equivalents | 1.9% |
PPH Performance
Total returns for PPH (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 1.1% |
| 1 year | 16.7% |
| 3 years (annualised) | 12.6% |
| 5 years (annualised) | 10.7% |
PPH Risk Information
Risk metrics for PPH, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 17.0%
PPH Costs and Fees
PPH costs about $36 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.36%
- Gross expense ratio: 0.36%
- Portfolio turnover: 30%
- Brokerage commissions: 1.67 bps of average net assets (SEC N-CEN)
PPH Cashflows
Over the 12 months to 2026-03, VanEck Pharmaceutical ETF had net inflows of $488.22M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | $64.96M |
| 2026-02 | $77.99M |
| 2026-01 | −$141.24M |
| 2025-12 | $88.95M |
| 2025-11 | −$110.32M |
| 2025-10 | $627.61M |
PPH Debt Constituents
No individual debt constituents are reported in VanEck Pharmaceutical ETF's latest SEC N-PORT filing.
PPH Prospectus and SEC Filings
Official VanEck Pharmaceutical ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other Global (incl. US) Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.